DE69935866D1 - Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe - Google Patents

Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe

Info

Publication number
DE69935866D1
DE69935866D1 DE69935866T DE69935866T DE69935866D1 DE 69935866 D1 DE69935866 D1 DE 69935866D1 DE 69935866 T DE69935866 T DE 69935866T DE 69935866 T DE69935866 T DE 69935866T DE 69935866 D1 DE69935866 D1 DE 69935866D1
Authority
DE
Germany
Prior art keywords
based vaccine
vaccine adjuvant
formyl methionyl
methionyl peptide
formyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69935866T
Other languages
English (en)
Other versions
DE69935866T2 (de
Inventor
Jeannine Alexander
William I Cox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connaught Technology Corp
Original Assignee
Connaught Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Technology Corp filed Critical Connaught Technology Corp
Publication of DE69935866D1 publication Critical patent/DE69935866D1/de
Application granted granted Critical
Publication of DE69935866T2 publication Critical patent/DE69935866T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69935866T 1998-12-18 1999-12-17 Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe Expired - Lifetime DE69935866T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US216702 1998-12-18
US09/216,702 US6017537A (en) 1998-12-18 1998-12-18 Formyl methionyl peptide vaccine adjuvant
PCT/US1999/030188 WO2000035482A2 (en) 1998-12-18 1999-12-17 Novel adjuvant for subunit or component vaccines

Publications (2)

Publication Number Publication Date
DE69935866D1 true DE69935866D1 (de) 2007-05-31
DE69935866T2 DE69935866T2 (de) 2008-01-10

Family

ID=22808169

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69935866T Expired - Lifetime DE69935866T2 (de) 1998-12-18 1999-12-17 Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe
DE69943170T Expired - Lifetime DE69943170D1 (de) 1998-12-18 1999-12-17 Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69943170T Expired - Lifetime DE69943170D1 (de) 1998-12-18 1999-12-17 Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten

Country Status (15)

Country Link
US (1) US6017537A (de)
EP (2) EP1800692B1 (de)
JP (1) JP2002532436A (de)
AT (2) ATE359817T1 (de)
AU (1) AU773697B2 (de)
CA (2) CA2342609C (de)
CY (2) CY1106635T1 (de)
DE (2) DE69935866T2 (de)
DK (2) DK1140166T3 (de)
ES (2) ES2284285T3 (de)
HK (1) HK1110769A1 (de)
NZ (1) NZ510544A (de)
PT (2) PT1800692E (de)
SI (2) SI1140166T1 (de)
WO (1) WO2000035482A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
BR0111083A (pt) * 2000-05-23 2003-04-08 Histatek Llc Método para tratar uma indicação que resulta de uma subunidade alfa 6 contendo condição patológica mediada por integrina em um mamìfero, para modular a função de uma subunidade alfa 6 contendo integrina, para modular uma subunidade alfa 6 contendo resposta mediada por integrina, para modular uma resposta mediada por integrina e para identificar um subunidade alfa 6 contendo agente de modificação de caminho de transdução de sinal mediada por integrina, e, complexos de superfìcie de célula e de receptor de superfìcie de célula
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP2004521867A (ja) * 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
EP1545575A4 (de) 2002-09-19 2006-04-05 Us Gov Health & Human Serv P. ariasi polypeptide, p. perniciosus polypeptide und anwendungsverfahren
EP1572968B1 (de) 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis-polypeptide und verwendungsverfahren
JP2006526389A (ja) * 2003-01-07 2006-11-24 ニューロームド テクノロジーズ、インク． 蛍光ｔ型チャネルアッセイ
WO2005115444A2 (en) * 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
US9248127B2 (en) * 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US7887522B2 (en) * 2005-03-18 2011-02-15 The Procter And Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
ES2620789T3 (es) 2005-08-15 2017-06-29 Altimmune Inc. Inmunización de aves por administración de vacunas con vectores no replicantes
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP2035041B1 (de) * 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Konjugate für die immanente immuntherapie bei krebs
CA2671929C (en) * 2006-12-04 2013-03-19 The Procter & Gamble Company Absorbent articles comprising graphics
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US9400873B2 (en) 2011-12-21 2016-07-26 Deka Products Limited Partnership System, method, and apparatus for dispensing oral medications
EP3187585A1 (de) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
SI2734230T1 (sl) 2011-07-20 2019-04-30 Merial Limited Rekombinantno cepivo proti virusu mačje levkemije, ki vsebuje optimiziran gen ovojnice virusa mačje levkemije
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2827897B1 (de) 2012-03-20 2018-10-31 Merial, Inc. Rekombinanter impfstoff gegen den pferde-herpesvirus-1 mit mutiertem glycoprotein c und verwendungen davon
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CA2948845C (en) 2014-05-14 2022-05-31 Merial, Inc. Methods for freeze-drying and rehydrating biologics
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
KR20230009631A (ko) * 2021-07-09 2023-01-17 포항공과대학교 산학협력단 포밀 메티오닌 특이 항체 제조를 위한 신규한 항원 펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Also Published As

Publication number Publication date
DK1800692T3 (da) 2011-03-28
WO2000035482A3 (en) 2000-10-26
HK1110769A1 (en) 2008-07-25
ES2358540T3 (es) 2011-05-11
CY1111372T1 (el) 2015-08-05
SI1800692T1 (sl) 2011-05-31
JP2002532436A (ja) 2002-10-02
CA2718376A1 (en) 2000-06-22
US6017537A (en) 2000-01-25
EP1140166A2 (de) 2001-10-10
AU773697B2 (en) 2004-06-03
NZ510544A (en) 2003-04-29
PT1140166E (pt) 2007-06-27
DK1140166T3 (da) 2007-07-02
EP1800692B1 (de) 2011-01-26
EP1140166B1 (de) 2007-04-18
DE69943170D1 (de) 2011-03-10
ES2284285T3 (es) 2007-11-01
EP1800692A1 (de) 2007-06-27
AU2845100A (en) 2000-07-03
WO2000035482A2 (en) 2000-06-22
ATE496630T1 (de) 2011-02-15
CA2342609A1 (en) 2000-06-22
SI1140166T1 (sl) 2007-08-31
ATE359817T1 (de) 2007-05-15
PT1800692E (pt) 2011-03-31
CY1106635T1 (el) 2012-01-25
DE69935866T2 (de) 2008-01-10
CA2342609C (en) 2010-11-16

Similar Documents

Publication Publication Date Title
DE69935866D1 (de) Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
DK0608261T3 (da) Sammensætninger med immunreaktivt hepatitis C virus polypeptid
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
ES2075440T3 (es) Vacuna contra la hepatitis b.
NO950668D0 (no) Peptider avledet fra et retrovirus fra HIV-gruppen og anvendelser derav
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
DK0575317T3 (da) Rekombinant anticoccidie-vaccine
DK0895538T3 (da) Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
NO924271L (no) Vaksiner med forbedret immunogenisitet
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
ATE174963T1 (de) Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum
PL442478A1 (pl) Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
Qin et al. Immune response in Balb/c mice induced by recombinant spike protein of severe acute respiratory syndrome coronavirus
BE905492A (fr) Vaccin contre le syndrome immunodeficitaire acquis et intermediaires antigeniques pour dosages immunologiques de depistage de ce syndrome.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition